Idiopathic Inflammatory Myopathies
Information
- Disease name
- Idiopathic Inflammatory Myopathies
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT03918356 | Completed | N/A | Application of Electrical Impedance Myography (EIM) as a Potential Biomarker of Idiopathic Inflammatory Myopathies | June 1, 2019 | May 30, 2021 |
| NCT00341679 | Completed | Studies of the Natural History and Pathogenesis of Autoimmune/Connective Tissue Diseases | July 13, 2005 | ||
| NCT03092167 | Completed | N/A | Physical Training in Patients With Idiopathic Inflammatory Myopathies | January 2017 | April 29, 2021 |
| NCT00055055 | Completed | Study of Families With Twins or Siblings Discordant for Rheumatic Disorders | April 21, 2003 | ||
| NCT03267277 | Completed | Phase 2/Phase 3 | Sodium Thiosulfate for Treatment of Calcinosis Associated With Juvenile and Adult Dermatomyositis | October 5, 2017 | November 9, 2023 |
| NCT04208464 | Completed | Phase 2 | JAK 1/2 Inhibitor, Baricitinib, in the Treatment of Adult IIM | October 7, 2021 | September 25, 2023 |
| NCT06417398 | Not yet recruiting | Early Phase 1 | Preliminary Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases | May 14, 2024 | May 1, 2025 |
| NCT06152172 | Not yet recruiting | Phase 1 | CARTIMMUNE: Study of Patients With Autoimmune Diseases Receiving KYV-101 | June 2024 | June 2028 |
| NCT06285539 | Not yet recruiting | Phase 2 | Drug Rediscovery for Rare Immune Mediated Inflammatory Diseases | March 2024 | December 2026 |
| NCT06306547 | Not yet recruiting | Clinical Study Cohort of Idiopathic Inflammatory Myositis | April 1, 2024 | April 1, 2034 | |
| NCT06350110 | Not yet recruiting | Phase 1/Phase 2 | Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE) | November 10, 2024 | December 28, 2025 |
| NCT04792931 | Recruiting | N/A | Adult Autoimmune Myopathies (MAIA) | May 20, 2022 | May 20, 2030 |
| NCT05199246 | Recruiting | N/A | Assessment of Safety and Acute Effects of a Lower-limb Powered Dermoskeleton in Patients With Neuromuscular Disorders | December 1, 2021 | July 2024 |
| NCT05200702 | Recruiting | N/A | Assessment of Safety and Acute Effects of a Knee-hip Powered Soft Exoskeleton in Patients With Neuromuscular Disorders | January 5, 2022 | July 2024 |
| NCT05400889 | Recruiting | Phase 2 | Clinical Characteristics and Mechanism Research of Inhibitors of Janus Kinase in the Idiopathic Inflammatory Myopathies | June 10, 2022 | June 1, 2023 |
| NCT05833711 | Recruiting | Phase 2 | Study Evaluating Efficacy and Safety of Froniglutide (PF1801) in Patients With Idiopathic Inflammatory Myopathy | September 5, 2023 | September 2025 |
| NCT05879419 | Recruiting | Phase 4 | Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases | May 23, 2023 | May 22, 2027 |
| NCT05952531 | Recruiting | Early Phase 1 | Characterizing Myositis With 68Ga-FAPI PET/CT | July 1, 2023 | July 2025 |
| NCT06316076 | Recruiting | Phase 1 | Safety and Efficacy Study of CD19-CAR-DNT Cells in Autoimmune Diseases | October 30, 2023 | June 2026 |
| NCT03092180 | Recruiting | Optimizing Treatment on Idiopathic Inflammatory Myopathies | January 2005 | May 7, 2024 | |
| NCT06361745 | Recruiting | N/A | Early Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases | April 2, 2024 | March 1, 2025 |
| NCT04561557 | Recruiting | Early Phase 1 | Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System | September 22, 2020 | May 31, 2027 |
| NCT03897803 | Unknown status | Elastography in Patients With Idiopathic Inflammatory Myopathies | April 15, 2019 | November 1, 2020 | |
| NCT04664465 | Unknown status | PRediction Of DIverse Glucocorticoids toxIcity OUtcomeS | March 18, 2021 | March 18, 2024 | |
| NCT04034199 | Unknown status | Phase 3 | Treating Idiopathic Inflammatory Myopathies Related Reduced Bone Mineral Density With Denosumab or Zoledronic Acid | August 15, 2019 | March 31, 2021 |